Price to earnings forward of Amphastar Pharmaceuticals, Inc. – NASDAQ:AMPH
The article focuses on the "Price to earnings forward" metric for Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) as displayed on TradingView. It provides a snapshot of this financial data point, indicating that the market is currently closed with no trades. The majority of the content consists of navigation links, product offerings, community features, and legal disclaimers from the TradingView platform.
Price to earnings forward of Amphastar Pharmaceuticals, Inc. – DUS:29A
This article provides financial information for Amphastar Pharmaceuticals, Inc. (DUS:29A) on the Dusseldorf Stock Exchange. It specifically highlights the company's price to earnings forward metric. The content largely consists of navigation and technical information related to TradingView and financial data providers.
Enterprise value to revenue forward of Amphastar Pharmaceuticals, Inc. – NASDAQ:AMPH
This article focuses on the enterprise value to revenue forward metric for Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH). It appears to be a financial data snippet from TradingView, providing an overview of this specific financial ratio for the company. The content primarily displays the company's stock information and general financial market context without further analytical details.
Enterprise value to EBIT forward of Amphastar Pharmaceuticals, Inc. – NASDAQ:AMPH
This article identifies the enterprise value to EBIT forward for Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH). It is a finance-related piece from TradingView, which also provides additional market and financial data for the company. The article itself is a placeholder or title for specific financial data not explicitly provided in the content.
Crude Oil Gains 2%; Comcast Shares Spike Higher
U.S. stocks showed strong performance today, with the Dow Jones, NASDAQ, and S&P 500 all trading higher. Communication services led the gains, while materials stocks declined. Several individual companies experienced significant stock movements, notably Comcast (CMCSA) surging on news of a spin-off, and Amphastar Pharmaceuticals (AMPH) falling after an analyst downgrade.
Amphastar Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $22, Implies 1% Upside
Amphastar Pharmaceuticals, Inc. (AMPH) has seen its average 12-month price target cut from $22.83 to $22 by analysts, with a range of $19 to $30 per share. This new target implies a modest 1% potential upside from its June 26 closing price. The consensus rating among seven analysts remains "Hold," with no "Buy" recommendations.
Amphastar Pharmaceuticals, Inc.(NasdaqGS: AMPH) added to Russell 2000 Dynamic Index
Amphastar Pharmaceuticals, Inc. (NasdaqGS: AMPH) has been added to the Russell 2000 Dynamic Index, effective June 28, 2026. This news comes shortly after the company was dropped from several other Russell Growth benchmarks. The biopharmaceutical company focuses on developing and commercializing generic and proprietary injectable, inhalation, and intranasal products, and recently received FDA approval for its over-the-counter Rextovy Naloxone Nasal Spray.
Price to sales forward of Amphastar Pharmaceuticals, Inc. – NASDAQ:AMPH
This article provides a brief snapshot of the "Price to sales forward" metric for Amphastar Pharmaceuticals, Inc. (AMPH) on the Nasdaq Stock Market. It indicates the stock market is closed with no trades. The main content focuses on navigation and related financial data services rather than detailed financial analysis.
Enterprise value to revenue forward of Amphastar Pharmaceuticals, Inc. – LS:A11664
This article focuses on the enterprise value to revenue forward metric for Amphastar Pharmaceuticals, Inc. (LS:A11664) as presented on TradingView. It appears to be a stub or data-focused page without detailed analysis, indicating that this financial metric is being tracked for the company.
Price to earnings forward of Amphastar Pharmaceuticals, Inc. – LS:A11664
This article displays the "Price to earnings forward" metric for Amphastar Pharmaceuticals, Inc. (LS:A11664) from TradingView. The content indicates that the market is closed and no trades have occurred for this specific data point. It is presented within the context of financial data provided by ICE Data Services and FactSet.
AMPH Forecast — Price Target — Prediction for 2027
This article provides a forecast for Amphastar Pharmaceuticals, Inc. (AMPH) stock, including analyst price targets, historical performance data, and financial metrics. It also addresses frequently asked questions about the company's stock, such as earnings reports, revenue, net income, market capitalization, and dividend policy. The article notes that analysts have a max estimate of $30.00 and a min estimate of $19.00 for AMPH's future price.
Amphastar Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AMPH)
This article provides an overview of Amphastar Pharmaceuticals, Inc. (AMPH) stock, including its current price, market capitalization, and historical performance. It details analyst forecasts with maximum and minimum price estimates, recent financial results, and future earnings and revenue expectations. The article also addresses frequently asked questions about dividends, employee count, EBITDA, and how to trade AMPH stock.
Amphastar Pharmaceuticals Inc (AMPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Amphastar Pharmaceuticals Inc (AMPH), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. The analysis indicates that AMPH's current price momentum score is 6.46, placing it 113th in the Pharmaceuticals industry, with the stock trading between a resistance level of 20.16 and a support level of 17.12. Technical indicators and moving averages predominantly signal a "Sell," with 0 buy signals and 3 sell signals from indicators, and 0 buy signals and 6 sell signals from moving averages.
AMPH Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Amphastar Pharmaceuticals, Inc (AMPH), indicating a "Strong Sell" consensus based on various technical indicators and moving averages. The analysis highlights that AMPH's share price is currently $18.81, trading below its 60-day and 200-day moving averages, suggesting a bearish trend. Key support and resistance levels are identified, along with specific oscillator readings like RSI and MACD, which largely support the "Strong Sell" recommendation.
Amphastar Pharmaceuticals Inc (AMPH) Financial Health: Profitability & Balance Sheet Analysis
This article provides an analysis of Amphastar Pharmaceuticals Inc (AMPH)'s financial health, noting its stable financial status and high operating efficiency, with a current financial score of 8.76. The company's latest quarterly revenue increased by 0.38% year-over-year, and its net profit saw a significant 74.61% year-over-year increase. It highlights various financial dimensions such as quality of earnings, operational efficiency, growth potential, and shareholder returns, although specific data points for these categories have not yet been disclosed by the company.
Amphastar Pharmaceuticals Inc (AMPH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Amphastar Pharmaceuticals Inc (AMPH) by business segment and geographical region. It highlights that "Other products" and "BAQSIMI" are the largest revenue contributors, while the United States accounts for the vast majority of the company's regional revenue. The data presented is dated as of April 6 and includes current stock information from June 18.
Amphastar Pharmaceuticals Inc (AMPH) Institutional Confidence
Amphastar Pharmaceuticals Inc (AMPH) has an institutional shareholding score of 7.00, placing it 51st out of 157 in the Pharmaceuticals industry. The current institutional shareholding proportion is 79.72%, which is a 6.44% decrease quarter-over-quarter. James Simons is the largest institutional shareholder, holding 1.24% of outstanding shares, though his holdings decreased by 1.29%.
Amphastar Pharmaceuticals Inc (AMPH) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Amphastar Pharmaceuticals Inc (AMPH) focusing on its dividend and stock split history. It notes that no dividends have been distributed by the company over the past five years and no stock split data is available. The page also presents current stock performance metrics like market cap and P/E ratio.
Amphastar Pharmaceuticals Inc (AMPH) Earnings Forecast: Future EPS & Revenue Growth Estimates
Amphastar Pharmaceuticals Inc (AMPH) has an earnings forecast score of 6.00, ranking 132nd in the Pharmaceuticals industry. Analysts have set an average price target of $31.00 for AMPH, with a "Hold" rating based on 7 analysts. The company's expected revenue for the next quarter is $182.48 million, and its EPS for the previous quarter was $0.53, with an expectation of $0.64 for the next quarter.
(AMPH) Price Dynamics and Execution-Aware Positioning
This article provides an in-depth analysis of Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) stock, highlighting strong near and mid-term sentiment but a weak long-term outlook. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis indicating support and resistance levels. The report also notes an exceptional risk-reward short setup.
AMPH: Updated Outlook And Q1 Reset Will Support Future Upside Potential
Amphastar Pharmaceuticals has seen its average analyst price target cut from $26.86 to $22.83 following recent Q1 results and a revised 2026 outlook. This adjustment reflects increased uncertainty regarding future revenue and margin projections, particularly concerning the potential interchangeability status of AMP-004. Despite the target reductions and more cautious sentiment, analysts largely maintain "Equal Weight" ratings, suggesting the stock remains investable as the company navigates these revised expectations.
Amphastar Pharmaceuticals, Inc. Shareholders Are Encouraged
Johnson Fistel, PLLP is investigating Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) for potential federal securities law violations after the company's stock price dropped over 20% following its Q1 2026 financial results. Amphastar reported a 15% decrease in BAQSIMI revenues due to lower average selling prices driven by higher rebates and pharmacy discounts, despite an increase in units sold. The investigation focuses on whether Amphastar executives were transparent about these pricing pressures.
Amphastar Pharmaceuticals sees generic Atrovent fueling 2026 growth despite BAQSIMI drag
Amphastar Pharmaceuticals anticipates significant growth in 2026, driven primarily by its generic Atrovent product. This projected growth is expected to occur despite a potential drag from its BAQSIMI product. The company is positioning its generic offering as a key revenue driver for the future.
Amphastar (AMPH) director awarded 8,143 RSUs and 17,365 stock options
Amphastar Pharmaceuticals director David Russell Gaugh was granted 8,143 restricted stock units (RSUs) and 17,365 stock options as part of his compensation. The RSUs and stock options all vest on June 1, 2027, with the options having an exercise price of $18.42 per share and an expiration date of June 1, 2036. Following these awards, Gaugh directly holds 14,447 shares of Common Stock.
Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag
Amphastar Pharmaceuticals expects mid- to high-single-digit revenue growth in 2026, driven primarily by its newly launched generic version of Atrovent, which currently enjoys six months of market exclusivity and could generate significant annual sales. Despite pricing pressures on its BAQSIMI product due to 340B-related issues, the company anticipates mitigation efforts to ease this impact. Amphastar also has biosimilar insulin aspart under regulatory review for a 2027 launch and continues to focus on pipeline development and strategic capital allocation.
Amphastar Pharmaceuticals (AMPH) director receives RSUs and options grant
Amphastar Pharmaceuticals director Richard K. Prins reported new equity awards, including 8,143 restricted stock units and a stock option for 17,365 shares, both vesting on June 1, 2027. The report also noted a prior bona fide gift of 1,500 shares. Following these transactions, Prins beneficially owned 37,598 shares of Amphastar Common Stock as of June 1, 2026.
Amphastar (AMPH) director awarded RSUs and options with tax withholding update
Amphastar Pharmaceuticals, Inc. director Lee Howard reported new equity compensation. He received 8,143 restricted stock units (RSUs) vesting June 1, 2027, and stock options for 17,365 shares with an exercise price of $18.42, expiring in 2036. Additionally, 769 shares of Common Stock were withheld to cover tax liabilities associated with RSU vesting.
Deflin Gayle awarded RSUs and stock options at Amphastar (NASDAQ: AMPH)
Amphastar Pharmaceuticals director Deflin Gayle received equity compensation including 8,143 restricted stock units (RSUs) and stock options for 17,365 shares. These awards, which vest on June 1, 2027, are compensation-related rather than open-market transactions. Following these grants, Gayle directly holds 19,057 shares of Common Stock in addition to the newly granted options.
Amphastar (AMPH) director receives RSU and stock option grants
Amphastar Pharmaceuticals director Michael A. Zasloff received new equity awards, including 8,143 restricted stock units (RSUs) and stock options for 17,365 shares. These grants, which vest on June 1, 2027, are considered compensation rather than open-market purchases and increase his direct ownership to 37,667 shares. The stock options have an exercise price of $18.42 per share and expire on June 1, 2036.
Amphastar (AMPH) director Diane Gerst receives RSUs and stock option grant
Amphastar Pharmaceuticals director Diane G. Gerst received equity compensation, including 8,143 restricted stock units and a stock option for 17,365 shares with an exercise price of $18.42. All awards vest on June 1, 2027. Following these grants, she directly holds 31,899 shares of common stock.
Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag
Amphastar Pharmaceuticals expects mid- to high-single-digit revenue growth in 2026, driven by the launch of a generic version of Atrovent, growth in Primatene Mist, and API sales from China. While the nasal glucagon product BAQSIMI faces pricing pressure due to 340B "double discounting," the company anticipates this impact to ease with a new mitigation vendor and a recent price increase. Amphastar is also progressing with its biosimilar insulin aspart product, targeting a 2027 launch, and expanding its pipeline through in-licensed peptide-based assets.
Amphastar (AMPH) holders approve directors, EY auditor and annual say-on-pay
Amphastar Pharmaceuticals, Inc. stockholders approved key proposals at their annual meeting, including the election of three directors—David Gaugh, William J. Peters, and Jacob Liawatidewi—to serve until the 2029 annual meeting. They also ratified Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2026. Furthermore, stockholders approved the compensation of named executive officers on a non-binding basis and, in an advisory vote, expressed a preference for annual say-on-pay votes, which the board adopted.
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow
Amphastar Pharmaceuticals, Inc. (AMPH) presented a slide deck in conjunction with the Jefferies Global Healthcare Conference 2026. The presentation materials were published by the company for the event. This article provides access to these slides for investors and interested parties.
(AMPH) as a Liquidity Pulse for Institutional Tactics
This article analyzes Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) for institutional trading tactics, highlighting a near-term strong sentiment but persistent mid and long-term weakness. It details an exceptional risk-reward setup, along with specific position, momentum breakout, and risk hedging trading strategies derived from AI models for different time horizons.
Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference
Amphastar Pharmaceuticals, Inc. announced that CFO Bill Peters and EVP of Corporate Administration Jacob Liawatidewi will present at the 2026 Jefferies Healthcare Conference on June 3, 2026. The presentation will be webcast live on the company's website and will be available for 30 days. Amphastar focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, and also sells active pharmaceutical ingredients.
Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference
Amphastar Pharmaceuticals, Inc. announced that CFO Bill Peters and EVP Jacob Liawatidewi will present at the 2026 Jefferies Healthcare Conference on June 3, 2026, at 4:55 p.m. ET. A webcast of the presentation will be available on the company's investor relations website for 30 days. Amphastar is a biopharmaceutical company specializing in generic and proprietary injectable, inhalation, and intranasal products.
Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference
Amphastar Pharmaceuticals, Inc. announced that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will present at the 2026 Jefferies Healthcare Conference on June 3, 2026, at 4:55 p.m. ET. A webcast of the presentation will be available on the company's investor relations website for 30 days. Amphastar is a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products.
8 Best Small Cap Pharma Stocks to Buy Right Now
This article lists the best small-cap pharma stocks, focusing on Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH). It details a recent downgrade by Wells Fargo due to revenue trajectory concerns and issues with a potential interchangeability status for AMP-004. Despite this, the company reported strong Q1 2026 results with progress in commercial base strengthening and pipeline advancements, including a new product launch and an exclusive licensing agreement.
Amphastar Pharmaceuticals Q1 2026: Revenue Miss and Pricing Pressures on BAQSIMI
Amphastar Pharmaceuticals reported flat revenue and missed adjusted profit forecasts in Q1 2026, causing a negative stock response. The company attributed these results to persistent price reductions, particularly for its diabetes treatment BAQSIMI, and increased competition. Analysts inquired about BAQSIMI's pricing challenges, timelines for synthetic corticotropin, insulin aspart biosimilar initiatives, and the market potential for new products, alongside concerns about future glucagon sales.
Pharma Earnings Season 2026: Amphastar Flat, Eli Lilly Surges in Q1 - News and Statistics
The pharmaceutical sector experienced mixed Q1 2026 earnings, with overall revenues exceeding analyst estimates by 1.5% but share prices declining by an average of 4.1%. Amphastar Pharmaceuticals reported flat revenues of $171.2 million, missing expectations and leading to a 25.1% stock drop. In contrast, Eli Lilly saw a significant surge, with revenues increasing 55.5% year-over-year to $19.8 billion, greatly surpassing analyst predictions.
Amphastar Pharmaceuticals' (NASDAQ:AMPH) Conservative Accounting Might Explain Soft Earnings
Amphastar Pharmaceuticals' recent earnings announcement did not impress shareholders, but an analysis suggests that unusual items significantly impacted profit. The company's profit was reduced by US$23 million due to these non-recurring items, implying that future earnings could improve if these expenses do not repeat. This indicates that Amphastar Pharmaceuticals' earnings potential might be better than the recent headline numbers suggest.
There May Be Some Bright Spots In Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings
Amphastar Pharmaceuticals' recent earnings report was disappointing due to soft headline numbers and a significant US$23m expense from unusual items. However, Simply Wall St suggests that these unusual items are often not repeated, potentially leading to higher profits next year. The article advises investors to look beyond the immediate figures and consider the company's underlying earnings potential.
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Lower Today
Amphastar Pharmaceuticals (AMPH) stock is trading lower by 2.8% today after Wells Fargo downgraded the company's stock to 'Equalweight' from 'Overweight' and significantly lowered its price target from $30 to $19. This downgrade follows a 19.1% drop in the stock price six days prior due to disappointing first-quarter 2026 financial results, where the company missed profit expectations and reported a substantial decline in earnings. The stock is down 33.3% year-to-date and 42.7% below its 52-week high.
Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook
Amphastar Pharmaceuticals is addressing discount pressure on its BAQSIMI product, implementing third-party claims validation and a 3% price increase. Despite these challenges, the company maintains its full-year revenue outlook, supported by strong new product launches and plans to discontinue unprofitable international BAQSIMI markets. Management expects margin recovery through higher-margin launches and continued pipeline development.
Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook
Amphastar Pharmaceuticals is addressing significant "double discounting" pressure on its BAQSIMI product, primarily due to 340B programs, which impacted first-quarter sales. The company
Amphastar forecasts BAQSIMI revenue flat to up low single digits, with 3% list price increase
Amphastar Pharmaceuticals is projecting that revenue from its BAQSIMI product will be flat to slightly up by a low single-digit percentage. This forecast includes a 3% increase in the list price of BAQSIMI. This financial outlook provides insight into the company's expectations for one of its key products.
Amphastar Pharmaceuticals (NASDAQ:AMPH) Earns Neutral Rating from Piper Sandler
Piper Sandler reaffirmed its "neutral" rating on Amphastar Pharmaceuticals (NASDAQ:AMPH) but lowered its price target from $25 to $21, indicating a modest potential upside. This comes after the company reported Q1 earnings of $0.42 per share and revenue of $171.17 million, both missing analyst expectations. Other analysts have also adjusted their ratings and price targets, resulting in a consensus "Hold" rating and an average price target of $26.86 for AMPH.
Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Quarterly Earnings Results
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported disappointing quarterly earnings, missing analyst expectations with adjusted EPS of $0.42 and revenue of $171.2 million, largely due to a 15% decline in BAQSIMI sales. Despite negative sentiment and a significant drop in stock price, the company saw growth in other products like Primatene MIST and launched a new generic, AMP-007, while maintaining strong financial flexibility through operating cash flow and stock repurchases. Analysts have largely maintained a "Hold" rating on AMPH.
Amphastar Pharmaceuticals, Inc. $AMPH Shares Purchased by Denali Advisors LLC
Denali Advisors LLC significantly increased its stake in Amphastar Pharmaceuticals (NASDAQ:AMPH) during the fourth quarter, purchasing an additional 76,765 shares to own a total of 211,765 shares valued at $5.67 million. This increase in institutional ownership comes despite Amphastar reporting adjusted EPS of $0.42 on revenue of $171.2 million, missing analyst expectations. Analyst sentiment remains cautious, with a consensus "Hold" rating and several firms cutting price targets after the recent earnings miss, though management expects BAQSIMI revenue to remain stable.
Amphastar Pharmaceuticals (AMPH) Is Up 9.4% After Profit Falls Despite New Drug Launches And Licensing Deals
Amphastar Pharmaceuticals (AMPH) reported a 9.4% stock increase despite a significant drop in first-quarter 2026 profits, with net income falling to US$6.42 million and diluted EPS to US$0.14 due to higher costs. This occurred even after the launch of a new inhalation product and a licensing deal. The article highlights concerns about cost pressures impacting profitability and the tension between the company's investment in its pipeline and the immediate financial impact of increased expenses.
